CD274 and non-small cell lung carcinoma: In the study of pretreated patients with NSCLC, the rates of hyperprogressive disease (HPD) of patients receiving PD-1/PD-L1 inhibitors and single-agent chemotherapy were 13.8 and 5.1%, respectively (23).